DYVOX Stock Analysis: Dynavox | ST
Medical Instruments & Supplies | ST, Sweden | Market Cap: 6.693m SEK | 12M Return: -23.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.4M
EPS Trend: 90.0%
Qual. Beats: 0
Rev. Trend: 99.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dynavox Group AB, formerly Tobii Dynavox, is a Stockholm-based medical technology company specializing in Augmentative and Alternative Communication (AAC) solutions. The company develops integrated hardware and software systems designed for individuals with speech and motor impairments resulting from conditions such as ALS, autism, and cerebral palsy.
The business model relies on a multi-disciplinary approach that includes product development, clinical training, and navigating complex insurance reimbursement frameworks. In the assistive technology sector, revenue is frequently driven by government-funded healthcare programs and educational grants, which provide the primary financing for high-cost speech-generating devices.
The company maintains a global footprint with operations across North America, Europe, and Asia-Pacific. By controlling the full ecosystem of AAC-including specialized eye-tracking hardware and proprietary language software-the firm creates high switching costs and high barriers to entry within the niche medical supplies industry.
- U.S. Medicare and insurance reimbursement policy changes impact AAC adoption
- High gross margins sustained by proprietary software and hardware integration
- Strategic acquisitions expand market share in specialized assistive technology segments
- Organic revenue growth driven by increased clinical awareness of AAC solutions
| Net Income: 181.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.36 > 1.0 |
| NWC/Revenue: 17.30% < 20% (prev 8.75%; Δ 8.55% < -1%) |
| CFO/TA 0.09 > 3% & CFO 234.6m > Net Income 181.0m |
| Net Debt (1.08b) to EBITDA (432.0m): 2.49 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (106.7m) vs 12m ago 0.47% < -2% |
| Gross Margin: 68.27% > 18% (prev 68.81%; Δ -0.54% > 0.5%) |
| Asset Turnover: 109.0% > 50% (prev 105.7%; Δ 3.37% > 0%) |
| Interest Coverage Ratio: 5.60 > 6 (EBIT TTM 263.0m / Interest Expense TTM 47.0m) |
| A: 0.17 (Total Current Assets 1.11b - Total Current Liabilities 682.0m) / Total Assets 2.53b |
| B: 0.27 (Retained Earnings 683.0m / Total Assets 2.53b) |
| C: 0.12 (EBIT TTM 263.0m / Avg Total Assets 2.27b) |
| D: 0.36 (Book Value of Equity 663.0m / Total Liabilities 1.86b) |
| Altman-Z'' = 3.15 = A |
| DSRI: 1.05 (Receivables 527.0m/431.0m, Revenue 2.47b/2.13b) |
| GMI: 1.01 (GM 68.81% / 68.27%) |
| AQI: 0.91 (AQ_t 0.45 / AQ_t-1 0.49) |
| SGI: 1.16 (Revenue 2.47b / 2.13b) |
| TATA: -0.02 (NI 181.0m - CFO 234.6m) / TA 2.53b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at SEK 63.85 with a total of 120,542 shares traded. Over the past week, the price has changed by +1.03%, over one month by -11.26%, over three months by -26.04% and over the past year by -23.21%.
Current recommended Stop Loss: 59.60 (which is 6.7% or 1.3 ATR below the current price).
Dynavox has no consensus analysts rating.
P/E Trailing = 37.3373
P/S = 2.7052
P/B = 10.4465
Revenue TTM = 2.47b SEK
EBIT TTM = 263.0m SEK
EBITDA TTM = 432.0m SEK
Long Term Debt = 829.0m SEK (from longTermDebt, last quarter)
Short Term Debt = 110.0m SEK (from shortTermDebt, last quarter)
Debt = 1.32b SEK (from shortLongTermDebtTotal, last quarter) + Leases 212.0m
Net Debt = 1.08b SEK (calculated: Debt 1.32b - CCE 243.0m)
Enterprise Value = 7.77b SEK (6.69b + Debt 1.32b - CCE 243.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 263.0m / Interest Expense TTM 47.0m)
EV/FCF = 75.95x (Enterprise Value 7.77b / FCF TTM 102.3m)
FCF Yield = 1.32% (FCF TTM 102.3m / Enterprise Value 7.77b)
FCF Margin = 4.14% (FCF TTM 102.3m / Revenue TTM 2.47b)
Net Margin = 7.32% (Net Income TTM 181.0m / Revenue TTM 2.47b)
Gross Margin = 68.27% ((Revenue TTM 2.47b - Cost of Revenue TTM 785.0m) / Revenue TTM)
Gross Margin QoQ = 67.18% (prev 68.69%)
Tobins Q-Ratio = 3.08 (Enterprise Value 7.77b / Total Assets 2.53b)
Interest Expense / Debt = 3.56% (Interest Expense 47.0m / Debt 1.32b)
Taxrate = 18.92% (42.0m / 222.0m)
NOPAT = 213.2m (EBIT 263.0m * (1 - 18.92%))
Current Ratio = 1.63 (Total Current Assets 1.11b / Total Current Liabilities 682.0m)
Debt / Equity = 1.99 (Debt 1.32b / totalStockholderEquity, last quarter 663.0m)
Debt / EBITDA = 2.49 (Net Debt 1.08b / EBITDA 432.0m)
Debt / FCF = 10.53 (Net Debt 1.08b / FCF TTM 102.3m)
Total Stockholder Equity = 574.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.98% (Net Income 181.0m / Total Assets 2.53b)
RoE = 31.51% (Net Income TTM 181.0m / Total Stockholder Equity 574.4m)
RoCE = 18.74% (EBIT 263.0m / Capital Employed (Equity 574.4m + L.T.Debt 829.0m))
RoIC = 11.65% (NOPAT 213.2m / Invested Capital 1.83b)
WACC = 8.61% (E(6.69b)/V(8.01b) * Re(9.74%) + D(1.32b)/V(8.01b) * Rd(3.56%) * (1-Tc(0.19)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 8.99 | Cagr: 0.04%
[DCF] Terminal Value 72.12% ; FCFF base≈121.0m ; Y1≈106.1m ; Y5≈85.7m
[DCF] Fair Price = 2.28 (EV 1.32b - Net Debt 1.08b = Equity 242.0m / Shares 106.1m; r=8.61% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 90.05 | EPS CAGR: 40.27% | SUE: -0.60 | # QB: 0
Revenue Correlation: 99.45 | Revenue CAGR: 24.05% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=-14.29% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.70 | Chg30d=-12.50% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.95 | Chg30d=-2.32% | Revisions=-40% | GrowthEPS=+89.1% | GrowthRev=+13.1%
EPS next Year (2027-12-31): EPS=4.02 | Chg30d=-2.57% | Revisions=-40% | GrowthEPS=+36.2% | GrowthRev=+18.6%
[Analyst] Revisions Ratio: -67% (up=0, down=6)